IOBT News and Press, IO Biotech Inc. From 12/30/25

2025-12-30 14:10:00 ET The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three year highs despite market volatility, responding to breakthrough innovations and increased deals involving NASDAQ biotech stocks. After dropping to a low of 3,637.05 in October 2023, the ...

Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for the treatment of metastatic melanoma Five-year analysis of median progression free survival was 25.5 months These results reinforce the potential of immune-modulatory vac...

2025-11-27 07:20:44 ET Introduction As the year comes to an end, we must be thankful for the therapies that are in late clinical stages. Most importantly, patients are set to benefit immensely. But nearly every trial candidate has implications beyond just patients. The approval of a...

NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the Company’s participation in the 8 th Annual Evercore Healthcare Conferenc...

BioMedWire Editorial Coverage : As late-stage biotech pipelines mature, fair-value remeasurements under U.S. Generally Accepted Accounting Principles (“GAAP”) are emerging as critical indicators of tangible scientific and commercial progress. These revaluations provide a financial...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 4.9% to $4.27 on volume of 371,335,987 shares Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF) rose 12.9% to $0.4086 on volume of 347,470,717 shares PROSHARES TRUST (SQQQ) rose...

2025-11-14 08:31:24 ET More on IO Biotech IO Biotech, Inc. (IOBT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript Seeking Alpha’s Quant Rating on IO Biotech Historical earnings data for IO Biotech Financial information fo...

Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, although statistical significance on the PFS primary endpoint was narrowly missed Meeting sched...

Ensysce Biosciences Inc. (ENSC) is expected to report $-0.85 for Q3 2025 IO Biotech Inc. (IOBT) is expected to report $-0.31 for Q3 2025 Lifeward Ltd. (LFWD) is expected to report $-0.14 for Q3 2025 Life360 Inc. (LIF) is expected to report $0.03 for Q3 2025 Pixelworks Inc. (PXLW) ...

Pre-clinical data for IO Biotech’s next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vaccine-targeted modulation of immunosuppressive myeloid cells, including tumor-associated ma...